Libra Therapeutics, Inc., a private biotechnology company focused on developing innovative therapies to restore cellular balance and reduce neurodegeneration, has announced the appointment of Shawn A. Scranton, PharmD, as President and Chief Executive Officer. Dr. Scranton brings 30 years of…
On the morning of October 30, Ma Xin, a member of the Standing Committee of the Jiangsu Provincial Party Committee and Executive Vice Governor, visited Jiangsu Hansoh, a subsidiary of Hansoh Pharma. Accompanying him were Yang Xinchong, Secretary-General of the…
The 2024 American Society of Nephrology (ASN) Kidney Week conference took place at the San Diego Convention Center from October 23 to 27. During this event, a post-hoc analysis of Hansoh Pharma’s innovative drug, pegmolesatide (trade name: Saint Luolai), for…
On World Cities Day, the World Health Organization (WHO) launched a new report highlighting how urban areas can tackle the increasing challenges posed by noncommunicable diseases (NCDs) and injuries. As urbanization is expected to rise to 68% by 2050, the…
A new report titled “Refugee and Migrant Health System Review: Challenges and Opportunities for Long-Term Health System Strengthening in Uganda” was launched on October 15 by Uganda’s Ministry of Health in collaboration with the World Health Organization (WHO). The report…
The pharmaceutical industry is evolving toward sustainability, with increasing awareness of the need for eco-friendly practices. Therapeutic peptides and oligonucleotides (TIDES) present particular challenges due to their traditionally resource-heavy manufacturing processes. With the growing demand for TIDES therapies, the environmental…
Exciting, Challenging, and Insightful – This Is the Impression Pyry Simi, an 18-year-old from Tampere, Gained of the Pharmaceutical Industry After Spending a Day with Outi Vaarala, SVP of Innovative Medicines & R&D at Orion. Through the Job Shadow Day…
ScaleReady, in partnership with Wilson Wolf Manufacturing and Bio-Techne Corporation (NASDAQ: TECH), has announced that Luminary Therapeutics has been awarded a $300,000 G-Rex® Grant. This funding will facilitate rapid process development and IND-enabling studies for several novel CAR γδ T…
The World Health Organization (WHO) has released its latest report on tuberculosis (TB), revealing that 8.2 million people were newly diagnosed in 2023—the highest number since WHO began tracking TB globally in 1995. This increase, up from 7.5 million in…
Merck (NYSE: MRK), known as MSD in markets outside the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), have announced the launch of INTerpath-009, a pivotal Phase 3 randomized clinical trial assessing V940 (mRNA-4157), an investigational individualized neoantigen therapy,…
Walgreens is expanding its virtual healthcare service to enhance access for patients nationwide. As of October 1, Walgreens Virtual Healthcare is now available in 30 states, a significant increase from its initial launch in nine states. This expansion is designed…
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, and Moderna, Inc. (Nasdaq: MRNA), announced the launch of INTerpath-009, a Phase 3 randomized clinical trial investigating V940 (mRNA-4157), an individualized neoantigen therapy (INT), combined with KEYTRUDA® (pembrolizumab),…